BACKGROUND: The combination of fludarabine, cyclophosphamide, and rituximab (FCR) has produced improved response rates and a prolonged survival in patients with chronic lymphocytic leukemia (CLL). However, its therapeutic power is counterbalanced by significant hematologic toxicity. Persistent and new-onset cytopenia after the completion of FCR raise concern about disease recurrence, the development of therapy-related myeloid malignancies (TRMM), and infections. METHODS: A total of 207 patients with CLL who achieved complete response, complete response with incomplete bone marrow recovery, or nodular partial remission were analyzed after frontline FCR therapy. RESULTS: Three months after the completion of therapy, 35% of patients had developed grade 2 to 4 cytopenia (according to Common Terminology Criteria for Adverse Events [version 4.0]). Factors found to be associated with cytopenia at 3 months after therapy were older age, advanced Rai stage disease, and lower baseline blood counts. Moreover, patients with cytopenia were less likely to have completed 6 courses of therapy with FCR. At 6 months and 9 months after therapy, the prevalence of grade 2 to 4 cytopenia was 24% and 12%, respectively. No differences in progression-free survival and overall survival were noted between cytopenic and noncytopenic patients or between patients with persistent and new-onset cytopenia. The prevalence of TRMM was 2.3% and did not differ significantly between cytopenic and noncytopenic patients or between those with persistent and new-onset disease. Late infections were more common in patients who were cytopenic at 9 months (38%) and were mostly bacterial (67%). CONCLUSIONS: Cytopenia after the completion of therapy is a common complication of frontline FCR that improves over time, particularly for new-onset cases. The presence of persistent cytopenia (lasting up to 9 months after the completion of therapy) should not raise concern about CLL recurrence of the development of TRMM, but should encourage surveillance for bacterial infections for an additional 9 months.
BACKGROUND: The combination of fludarabine, cyclophosphamide, and rituximab (FCR) has produced improved response rates and a prolonged survival in patients with chronic lymphocytic leukemia (CLL). However, its therapeutic power is counterbalanced by significant hematologic toxicity. Persistent and new-onset cytopenia after the completion of FCR raise concern about disease recurrence, the development of therapy-related myeloid malignancies (TRMM), and infections. METHODS: A total of 207 patients with CLL who achieved complete response, complete response with incomplete bone marrow recovery, or nodular partial remission were analyzed after frontline FCR therapy. RESULTS: Three months after the completion of therapy, 35% of patients had developed grade 2 to 4 cytopenia (according to Common Terminology Criteria for Adverse Events [version 4.0]). Factors found to be associated with cytopenia at 3 months after therapy were older age, advanced Rai stage disease, and lower baseline blood counts. Moreover, patients with cytopenia were less likely to have completed 6 courses of therapy with FCR. At 6 months and 9 months after therapy, the prevalence of grade 2 to 4 cytopenia was 24% and 12%, respectively. No differences in progression-free survival and overall survival were noted between cytopenic and noncytopenic patients or between patients with persistent and new-onset cytopenia. The prevalence of TRMM was 2.3% and did not differ significantly between cytopenic and noncytopenic patients or between those with persistent and new-onset disease. Late infections were more common in patients who were cytopenic at 9 months (38%) and were mostly bacterial (67%). CONCLUSIONS:Cytopenia after the completion of therapy is a common complication of frontline FCR that improves over time, particularly for new-onset cases. The presence of persistent cytopenia (lasting up to 9 months after the completion of therapy) should not raise concern about CLL recurrence of the development of TRMM, but should encourage surveillance for bacterial infections for an additional 9 months.
Authors: L Ysebaert; E Gross; E Kühlein; A Blanc; J Corre; J J Fournié; G Laurent; A Quillet-Mary Journal: Leukemia Date: 2010-05-13 Impact factor: 11.528
Authors: D A Carney; D A Westerman; C S Tam; A Milner; H M Prince; M Kenealy; M Wolf; E H Januszewicz; D Ritchie; N Came; J F Seymour Journal: Leukemia Date: 2010-10-21 Impact factor: 11.528
Authors: Tadeusz Robak; Anna Dmoszynska; Philippe Solal-Céligny; Krzysztof Warzocha; Javier Loscertales; John Catalano; Boris V Afanasiev; Loree Larratt; Christian H Geisler; Marco Montillo; Ilya Zyuzgin; Peter S Ganly; Caroline Dartigeas; András Rosta; Jörg Maurer; Myriam Mendila; M Wayne Saville; Nancy Valente; Michael K Wenger; Sergey I Moiseev Journal: J Clin Oncol Date: 2010-03-01 Impact factor: 44.544
Authors: Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps Journal: Blood Date: 2008-01-23 Impact factor: 22.113
Authors: John C Byrd; Bercedis L Peterson; Vicki A Morrison; Kathleen Park; Robert Jacobson; Eva Hoke; James W Vardiman; Kanti Rai; Charles A Schiffer; Richard A Larson Journal: Blood Date: 2002-07-05 Impact factor: 22.113
Authors: Constantine J Karvellas; Filipe S Cardoso; Michelle Gottfried; K Rajender Reddy; A James Hanje; Daniel Ganger; William M Lee Journal: Clin Gastroenterol Hepatol Date: 2016-06-13 Impact factor: 11.382
Authors: John C Byrd; Peter Hillmen; Susan O'Brien; Jacqueline C Barrientos; Nishitha M Reddy; Steven Coutre; Constantine S Tam; Stephen P Mulligan; Ulrich Jaeger; Paul M Barr; Richard R Furman; Thomas J Kipps; Patrick Thornton; Carol Moreno; Marco Montillo; John M Pagel; Jan A Burger; Jennifer A Woyach; Sandra Dai; Remus Vezan; Danelle F James; Jennifer R Brown Journal: Blood Date: 2019-03-06 Impact factor: 25.476